ArticleFrontiers in oncology2024

Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3).

Susanne Jung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.